Evaxion Biotech A/S (EVAX)
NASDAQ: EVAX
· Real-Time Price · USD
2.17
0.10 (4.83%)
At close: Jun 18, 2025, 2:40 PM
Company Description
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections.
The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers.
Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases.
The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Evaxion Biotech A/S
| Country | DK |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Christian Kanstrup M.Sc. |
Contact Details
Address: Dr. Neergaards Vej Horsholm, DK | |
| Website | https://www.evaxion-biotech.com |
Stock Details
| Ticker Symbol | EVAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001828253 |
| CUSIP Number | 29970R303 |
| ISIN Number | US29970R3030 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christian Kanstrup M.Sc. | Chief Executive Officer |
| Thomas Frederik Schmidt M.Sc. | Interim Chief Financial Officer |
| Andreas Holm Mattsson | Founder & Chief AI Officer |
| Dr. Birgitte Rono Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 03, 2025 | 6-K | Filing |
| May 27, 2025 | 6-K | Filing |
| May 23, 2025 | 6-K | Filing |
| May 22, 2025 | 6-K | Filing |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 05, 2025 | 6-K | Filing |
| Apr 29, 2025 | 6-K | Filing |
| Apr 28, 2025 | 6-K | Filing |
| Apr 10, 2025 | 6-K | Filing |
| Apr 07, 2025 | 6-K | Filing |